摘要
目的系统评价生血宁治疗肾性贫血的临床效果。方法计算机检索Pub Med、Web of Science、维普、万方和中国知网数据库,查找关于生血宁片对比常规药物及常规疗法治疗肾性贫血的相关研究文献,检索时限均为建库至2017年8月,由两位评价员按纳入与排除标准独立筛选文献、提取资料并评价纳入研究的偏倚风险后,运用Stata 12.0软件进行统计分析。结果共纳入17项随机对照试验,包括1193例肾性贫血患者。Meta分析结果显示,与常规治疗及其他铁剂比较,生血宁片能明显改善肾性贫血患者的各项实验室指标:血红蛋白[WMD=1.52,95%CI(1.18,1.86),P<0.001]、血细胞比容[WMD=1.90,95%CI(1.19,2.60),P<0.001]、血清铁蛋白[WMD=2.01,95%CI(1.38,2.65),P<0.001]和血清转铁蛋白饱和度[WMD=1.90,95%CI(1.30,2.50),P<0.001],差异均有统计学意义。结论目前研究显示,生血宁片治疗肾性贫血是有效的。受纳入研究质量和数量所限,本研究结论可能存在偏倚,需要开展更多高质量的研究予以证明。
Objective To systematically review the effectiveness of Shengxuening tablet for renal anemia. Methods We electronically searched databases including Pubmed, Web of Science, VIP, WanFang Data and CNKI for published arti- cles of randomized controlled trials （RCTs） of Shengxuening tablets versus other drugs and conventional drugs for renal anemia from inception to August 2017. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data and assessed the risk of bias in included studies. Then, Meta-analyses was per- formed with Stata 12.0 software. Results A total of 17 RCTs involving 1193 patients with renal anemia were included. The results of Meta-analyses showed that the improvement of laboratory indications, such as Hemoglobin [WMD = 1.52, 95%CI （1.18, 1.86）, P 〈 0.001], Hematocrit [WMD = 1.90, 95%CI （1.19, 2.60）, P 〈 0.001], Serum Ferritin [WMD = 2.01, 95%CI （1.38, 2.65）, P 〈 0.001] and Transferrin Saturation [WMD = 1.90, 95%CI （1.30, 2.50）, P 〈 0.001]. Con- clusion The current evidence shows that Shengxuening tablet may significantly improve the effectiveness. Due to the limited quality and quantity of the included studies, the above conclusions need more high quality studies to verify.
出处
《中国医药导报》
CAS
2018年第4期120-125,共6页
China Medical Herald
